Beam Therapeutics (BEAM) Q4 2025 Earnings
How Did BEAM Stock React to Q4 2025 Earnings?
S&P 500 over the same 30 days: −6.15%.
Did BEAM Beat Earnings? Q4 2025 Results
Yes. Beam Therapeutics reported Q4 2025 earnings of $2.33 a share on Feb 24, 2026, beating the $-1.12 consensus estimate by 309.0%. Revenue was $114.1M against a $12.9M estimate.
Beam Therapeutics delivered a striking earnings beat in Q4 2025, posting adjusted EPS of $2.33 against a consensus estimate of negative $1.01, a positive surprise of 330.69%, while revenue of $114.11 million cleared the $12.86 million consensus by 787.07% and rose 279.5% from the year-ago quarter. The headline driver was a $255.15 million gain on the sale of an equity method investment, which pushed the company to GAAP net income of $244.30 million compared to a net loss of $90.35 million a year earlier; absent that one-time item, Beam would have remained in the red. Revenue itself was propelled by Pfizer's opt-in to an exclusive worldwide license for a liver-targeted development candidate, concluding a four-year research collaboration. Looking ahead, Beam extended its cash runway into mid-2029, supported by a $1.25 billion year-end cash position and a new $500.00 million credit facility with Sixth Street, with key catalysts including a potential BLA submission for risto-cel in sickle cell disease as early as year-end 2026 and updated BEAM-302 data expected by the close of Q1 2026.
- Gain on sale of equity method investment of $255.1 million drove Q4 net income
- License and collaboration revenue of $114.1 million in Q4 2025 versus $30.1 million in Q4 2024, reflecting Pfizer collaboration activities
- Strong cash position of $1.25 billion at year-end bolstered by collaboration payments and financing
“In 2025, we established base editing as a best-in-class technology for genetic medicine, with positive proof-of-concept data and regulatory and clinical development paths to approval across multiple high-value programs.”
Beam Therapeutics CEO, on the earnings call
What Was Beam Therapeutics's Outlook in Q4 2025?
Beam expects its cash, cash equivalents, and marketable securities as of December 31, 2025 ($1.25 billion), combined with the anticipated $200 million minimum drawdown from the Sixth Street credit facility, to fund operations into mid-2029. Key 2026 milestones include: updated Phase 1/2 data and pivotal development path for BEAM-302 in AATD by end of Q1 2026; potential BLA submission for risto-cel in SCD as early as year-end 2026; IND filing for BEAM-304 in PKU in 2026; initial clinical data for BEAM-301 in GSDIa in 2026; and completion of BEAM-103 dosing in the first half of 2026.
BEAM YoY Financials
| Metric | Q4 2025 | Q4 2024 | Year over year |
|---|---|---|---|
| Revenue | $114.1M | $30.1M | +279.5% |
| Operating Income | −$17.4M | −$9.6M | +82.6% |
| Net Income | $244.3M | $51.9M | +370.4% |
Figures from SEC filings and company reports. Not investment advice.